Aclaris Therapeutics (NASDAQ:ACRS – Get Free Report) was downgraded by investment analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report released on Saturday, Wall Street Zen reports.
A number of other equities research analysts also recently weighed in on ACRS. Craig Hallum set a $9.00 target price on Aclaris Therapeutics in a research report on Wednesday, October 28th. Wedbush cut Aclaris Therapeutics from an “outperform” rating to a “neutral” rating and decreased their price target for the company from $8.00 to $3.00 in a report on Tuesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aclaris Therapeutics in a report on Monday, September 21st. Canaccord Genuity Group lowered their price objective on Aclaris Therapeutics from $13.00 to $12.00 and set a “buy” rating for the company in a research report on Tuesday. Finally, HC Wainwright reissued a “buy” rating and set a $16.00 price objective on shares of Aclaris Therapeutics in a report on Wednesday, October 28th. Three research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $10.67.
View Our Latest Analysis on ACRS
Aclaris Therapeutics Price Performance
Aclaris Therapeutics (NASDAQ:ACRS – Get Free Report) last issued its quarterly earnings results on Thursday, November 5th. The biotechnology company reported ($0.12) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.04. The business had revenue of $1.48 million during the quarter, compared to analyst estimates of $1.27 million. Aclaris Therapeutics had a negative net margin of 1,244.09% and a negative return on equity of 59.19%. On average, equities analysts expect that Aclaris Therapeutics will post -0.56 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Aclaris Therapeutics
A number of hedge funds have recently modified their holdings of the business. BlackRock Inc. bought a new position in shares of Aclaris Therapeutics during the 2nd quarter valued at about $53,096,000. Rock Springs Capital Management LP increased its stake in Aclaris Therapeutics by 0.4% during the 1st quarter. Rock Springs Capital Management LP now owns 4,472,650 shares of the biotechnology company’s stock worth $16,772,000 after purchasing an additional 18,909 shares in the last quarter. Braidwell LP raised its holdings in Aclaris Therapeutics by 26.1% during the 2nd quarter. Braidwell LP now owns 2,142,348 shares of the biotechnology company’s stock worth $11,333,000 after buying an additional 443,232 shares during the period. Palo Alto Investors LP acquired a new stake in Aclaris Therapeutics during the 2nd quarter worth approximately $8,535,045. Finally, Kalehua Capital Management LLC acquired a new stake in Aclaris Therapeutics during the 1st quarter worth approximately $6,871,000. Institutional investors and hedge funds own 98.34% of the company’s stock.
About Aclaris Therapeutics
Aclaris Therapeutics is a biopharmaceutical company focused on discovering and developing treatments for immuno-inflammatory diseases. Its research programs include small-molecule therapies designed to target pathways involved in inflammation and immune responses. The company’s development portfolio has included candidates for dermatologic and other inflammatory conditions. Aclaris previously developed ESKATA, a topical treatment for raised seborrheic keratoses that received U.S. regulatory approval in 2017.
Further Reading
- Five stocks we like better than Aclaris Therapeutics
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
